Who are ODM-108 Part III's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CHS-0214, BMS-986353, UGN-103, AK120, Placebo+AK111, KITE-753.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/odm-108-part-iii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ODM-108 Part III — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ODM-108 Part III (ODM-108 Part III) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Unknown — investigational small molecule. Area: Metabolic.

discontinued Unknown — investigational small molecule Not publicly disclosed Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

ODM-108 Part III (ODM-108 Part III) — Orion Corporation, Orion Pharma. ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ODM-108 Part III TARGET	ODM-108 Part III	Orion Corporation, Orion Pharma	discontinued	Unknown — investigational small molecule	Not publicly disclosed
CHS-0214	CHS-0214	Coherus Oncology, Inc.	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
BMS-986353	BMS-986353	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
UGN-103	UGN-103	UroGen Pharma Ltd.	phase 3	Small molecule	Not publicly disclosed
AK120	AK120	Akesobio Australia Pty Ltd	phase 3	Bispecific T cell engager	CD3 and tumor-associated antigen (specific target not publicly disclosed)
Placebo+AK111	Placebo+AK111	Akeso	phase 3	Bispecific T-cell engager (BiTE)	CD3 and tumor-associated antigen (specific target not publicly disclosed)
KITE-753	KITE-753	Kite, A Gilead Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Unknown — investigational small molecule class)

Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ODM-108 Part III — Competitive Intelligence Brief. https://druglandscape.com/ci/odm-108-part-iii. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab